摘要
为了探讨术前肝动脉栓塞(TAE)能否改善肝癌切除术预后,作者分析了肿瘤直径3cm以上,无门静脉癌栓的77例患者,术前是否行肝动脉化疗栓塞对肝癌切除术后疗效影响。77例患者按术前是否接受TAE分为栓塞组(A组,n=26)和非栓塞组(B组,n=51),每组按肿瘤直径再分A1、B1(3~8cm),A2、B2(>8.0cm)两个亚组。结果术后1、2、3年无瘤存活率各组分别为:A1组(n=14)为50.0%、33.3%、16.6%;B1组(n=33)为72.7%、54.2%、39.7%;A2组(n=12)为75.0%、56.2%、45.0%;B2组(n=18)为38.9%、32.4%、10.8%。术后1、3、5年存活率各组分别为:A1组为85.7%、31.2%、0;B1组为84.8%、58.7%、27.9%;A2组为91.6%、82.5%、53.0%;B2组为77.8%、30.1%、0。术后1、2、3年无瘤存活率和1、3、5年存活率A1组与B1组差异无显著意义,A2组与B2组差异有显著意义(P<0.05)。此外,同为术前TAE组,A1组术后无瘤存活率和5年存活率均低于A2组。结果表明对8.0cm以下可切除肝癌术前不宜?
Thisstudyconsistsof77hepatocelularcarcinomapatients.Twenty-six(GroupA)re-ceivedpreoperativeTAEand51didnot(GroupB).GroupAandBwerefutherdividedintotwosub-groupsaccordingtotheirtumorsizei.e.GroupA1andB1(tumorsize3~8cm);GroupA2andB2(tu-morsize>8cm).The1-,2-,3-yeardiseasefreesurvivalrateswere50.0%,33.3%,16.6%forGroupA1and72.7%,54.2%,39.7%forGroupB1;75.0%,56.2%,45.0%forGroupA2and38.9%,32.4%,10.8%forGroupB2respectively.The1-,3-,5-yearssurvivalrateswere85.7%,31.2%,0forGroupA1and84.8%,58.7%,27.9%forGroupB1;91.6%,82.5%,53.0%forGroupA2and77.8%,30.1%,0forGroupB2respectively.ThereweresignificantdiferencesbetweenGroupA2andB2bothindeseasefreesurvivalrateand5-yearsurvivalrate(P<0.05).TheresultsalsodemonstratedthatthepreoperativeTAEdidworsentheprognosisofpatientswithtumorsizebetween3~8cm(GroupA1)withdiseasefreesurvivalrateand5-yearsurvivalrateshorterthanthatofGroupA2.
出处
《中华外科杂志》
CAS
CSCD
北大核心
1996年第7期413-415,共3页
Chinese Journal of Surgery
关键词
肝细胞癌
肝切除
手术前
药物疗法
HepatocelularcarcinomaHepatectomyHepaticarterialchemoembolization